Meningeal involvement in Wegener's granulomatosis.
We describe a patient with Wegener's granulomatosis (WG) who developed neurological symptoms attributed to meningeal involvement. The diagnosis of WG was complicated by persistently negative antineutrophil cytoplasmic antibodies (ANCA) and lack of specificity in the histopathological findings from multiple anatomical sites. This rare neurological manifestation of WG was treated successfully with oral cyclophosphamide and the patient has continued remission for 3 years taking oral methotrexate.
Al Dhanhani
Ali
A
Division of Rheumatology, Department of Medicine, the Division of Anatomical Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
Macaulay
Robert
R
Maloney
Bill
B
Hanly
John G
JG
D000284:Administration, Oral; D000328:Adult; D002118:Calcium / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000627:therapeutic use; D014890:Granulomatosis with Polyangiitis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008581:Meningitis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome; D020293:Vasculitis, Central Nervous System / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D012968:Etidronic Acid; D002118:Calcium; D011241:Prednisone; D008727:Methotrexate